NCT01474135View on ClinicalTrials.gov

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

0.25% AR-12286 / 0.004% travoprost

DRUG

0.5% AR-12286, 0.004% travoprost

DRUG

0.004% Travoprost

Trial Locations (9)

12159

Glaucoma Consultants of the Capital Region, Slingerlands

14618

Rochester Ophthalmology Group, Rochester

44115

Abrams Eye Center, Cleveland

63090

Comprehensive Eye Care, St Louis

79902

Cataract & Glaucoma Center, El Paso

90301

United Medical Research Institute, Inglewood

92064

Centre For Health Care, Poway

92657

Aesthetic Eye Care Institute, Newport Beach

94954

Bacharach practice, Petaluma

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT01474135 - AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure | Biotech Hunter | Biotech Hunter